Blog

The place to get DiaCarta’s updates and latest
precision molecular diagnostics trends

KRAS Codon 12 Mutations and Detection

KRAS Codon 12 Mutations and Detection

Next-generation sequencing (NGS) is a powerful tool that has seen a fast increase in clinical labs although only a few NGS tests have been approved by the FDA. However, there have been a lot of debate on if variants from NGS sequencing should be confirmed either by Sanger sequencing, the gold standard, or other techniques such as quantitative PCR, or the combination, or other methods.
Read More
HPV-driven Cancers and Somatic Mutations in These Cancers

HPV-driven Cancers and Somatic Mutations in These Cancers

Next-generation sequencing (NGS) is a powerful tool that has seen a fast increase in clinical labs although only a few NGS tests have been approved by the FDA. However, there have been a lot of debate on if variants from NGS sequencing should be confirmed either by Sanger sequencing, the gold standard, or other techniques such as quantitative PCR, or the combination, or other methods.
Read More
cfDNA Quantitation for Research and Clinical Applications

cfDNA Quantitation for Research and Clinical Applications

Next-generation sequencing (NGS) is a powerful tool that has seen a fast increase in clinical labs although only a few NGS tests have been approved by the FDA. However, there have been a lot of debate on if variants from NGS sequencing should be confirmed either by Sanger sequencing, the gold standard, or other techniques such as quantitative PCR, or the combination, or other methods.
Read More
Confirmation of NGS for False-negative Variants Using XNA Technology

Confirmation of NGS for False-negative Variants Using XNA Technology

Next-generation sequencing (NGS) is a powerful tool that has seen a fast increase in clinical labs although only a few NGS tests have been approved by the FDA. However, there have been a lot of debate on if variants from NGS sequencing should be confirmed either by Sanger sequencing, the gold standard, or other techniques such as quantitative PCR, or the combination, or other methods.
Read More
XNA Molecular Clamps Help Identify False-positive T790M Mutation

XNA Molecular Clamps Help Identify False-positive T790M Mutation

Eighty five percent of the lung cancer patients are non-small cell lung cancer (NSCLC) patients. Among this population, patients with exon 19 deletion and L858R mutations respond well to the first (such as erlotinib and gefitinib) and second generation (such as afatinib and dacomitinib) of tyrosine kinase inhibitors (TKIs). However, all the respondents develop resistance after 9 to 14-month period and more than 50% of the resistance cases are due to the single point mutation at exon 20, T790M.
Read More
Cancer Diagnostics: Targeted Gene Panels for Next Generation of Sequencing

Cancer Diagnostics: Targeted Gene Panels for Next Generation of Sequencing

Read More
Colorectal Cancer: Early Screening Could Save Your Life

Colorectal Cancer: Early Screening Could Save Your Life

Read More
Detecting BRAF (V600E) Mutation in FFPE or Blood Samples

Detecting BRAF (V600E) Mutation in FFPE or Blood Samples

Read More
DiaCarta: Dedicated to the Science of Impact

DiaCarta: Dedicated to the Science of Impact

Read More
DiaCarta Redefining Molecular Diagnostics Through XNA

DiaCarta Redefining Molecular Diagnostics Through XNA

Read More
Case Study: DiaCarta – Translational Genomics Powered by Molecular Clamp Technology

Case Study: DiaCarta – Translational Genomics Powered by Molecular Clamp Technology

Read More
A Steadfast Dedication for Improving Therapeutic Options across the Globe: DiaCarta

A Steadfast Dedication for Improving Therapeutic Options across the Globe: DiaCarta

Read More
DiaCarta: Democratizing the Diagnosis Process

DiaCarta: Democratizing the Diagnosis Process

Read More
DiaCarta Demos Liquid Biopsy Use for ColoScape Assay, Plans to Market Expanded Application

DiaCarta Demos Liquid Biopsy Use for ColoScape Assay, Plans to Market Expanded Application

Read More
Leadership Teams from Sanpower Group and BVCF Visited DiaCarta Headquarters

Leadership Teams from Sanpower Group and BVCF Visited DiaCarta Headquarters

Read More

Need Help?

Call us: +1 (800) 878-6662

Email us: information@diacarta.com

Contact Us!

Ready to Subscribe and Learn?

Register and Learn!

Join our mailing list to receive the latest news and updates from our team.

You have Successfully Subscribed!

X